Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central anxious process, conolidine modulates alternate molecular targets. A Science Innovations analyze uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. B... https://elagabalusv580xso9.bloggerchest.com/profile